

11<sup>th</sup> World Congress on Alternatives

## Examples of How Data from in vitro Developmental Neurotoxicity Assays Are Being Used to Make Decisions About Chemicals

#### Timothy J Shafer, PhD

Biomolecular and Computational Toxicology Division Center for Computational Toxicology and Exposure

September 1, 2021



Phone: 919-541-0647 Shafer.tim@epa.gov



### **Disclosure Statement**

This work has been funded by the US. Environmental Protection Agency. I have no conflicts to declare.

**Disclaimer:** This is a scientific presentation only. Some or all of the data presented in this presentation are preliminary and subject to change. **Do not cite or quote this presentation.** 

This presentation does not represent EPA policy and mention of products or tradenames does not constitute a recommendation for use or endorsement.

## 

## **International Efforts on DNT NAMs**



TOXICOLOGICAL SCIENCES, 167(1), 2019, 45–57

doi: 10.1093/toxsci/kfy211 Advance Access Publication Date: November 23, 2018 Forum

#### FORUM

#### International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing

Magdalini Sachana,<sup>\*,1</sup> Anna Bal-Price,<sup>†</sup> Kevin M. Crofton,<sup>‡</sup> Susanne H. Bennekou,<sup>§</sup> Timothy J. Shafer,<sup>¶</sup> Mamta Behl,<sup>∥</sup> and Andrea Terron<sup>∥∣</sup>

#### Towards regulatory DNT testing: Alternative methods



Figure 1. Timeline of efforts to develop and implement new alternative methods for developmental neurotoxicity.

Table 2. Proposed Assays for Evaluation As an In Vitro DNT Battery

Process	Assays	References
Proliferation	hNP1 NPC1	Harrill et al. (2018) Baumann et al. (2016) and Barenys et al. (2017)
	UKN1	Balmer et al. (2012)
Apoptosis	hNP1	Harrill et al. (2018)
Migration	NPC2	Baumann et al. (2016) and Barenys et al. (2017)
	UKN2	Nyffeler et al. (2017)
Neuron differentiation	NPC3	Baumann et al. (2016) and Barenys et al. (2017)
Oligodendrocyte differentiation & maturation	NPC5/6	Baumann et al. (2016) and Barenys et al. (2017)
Neurite outgrowth	iCell gluta hN2	Harrill et al. (2018)
0	UKN 4 & 5	Krug et al. (2013)
	NPC4	Baumann et al. (2016) and Barenys et al. (2017)
Synaptogenesis	Rat primary synaptogenesis	Harrill et al. (2018)
Network formation	MEA-NFA	Brown et al. (2016) and Frank et al. (2018)



## **EPA DNT NAM Assays**

Proliferation

Neurite Outgrowth





Synaptogenesis



Apoptosis







Acute Network Function (MEA-AcN) and Network Formation Assay (NFA)

#### **SEPA DNT NAMs Coverage of Neurodevelopmental Processes** Apoptosis Synaptogenesis Apop Synap Neurite growth **MEA-NFA MEA-AcN** UKN4 & 5 Differentiation RatCort\_NOG UKN2 iCell NOG **NPC3-5** Proliferation Myelination Neural network hNP1 formation & function NPC6 UKN2 Migration NPC2

Aschner et al., 2016



## Examples of the use of DNT NAMs at EPA

- I. Screening Level information
  - APCRA, TSCA, PFAS
- **II. Structure-activity relationships** 
  - Apply DNT NAMS to evaluate structurally similar chemicals when one of the chemicals has known effects in a Guideline DNT study
    - Example with compound X and structurally similar analogs
      - DNT Guideline exists for X, should it be required for the analogs?
- **III. Weight of Evidence approaches** 
  - Organophosphates

## Example #1: Screening Level Information for PFAS Compounds

Problem: Perfluoroalkyl substances have recently been identified as environmental contaminants with significant human exposure. Little toxicological information is available for these compounds.

- Structurally diverse
- With the exception of a few specific congeners, little toxicological information
- Evidence of DNT is ambiguous,
  - epidemiological studies report positive and negative neurodevelopmental effects associated with exposure to PFAS

#### Assembled a PFAS Chemical Library for Research and Methods Development

- Attempted to procure ~3,000 based on chemical diversity, Agency priorities, and other considerations
- Obtained 480 total unique chemicals
  - 430/480 soluble in DMSO (90%)
  - 54/75 soluble in water (72%) (incl. only 3 DMSO insolubles)
  - Issues with sample stability and volatility
- Subset of PFAS Library for testing:

Hepatotoxicity Developmental toxicity Mitochondrial toxicity Developmental neurotoxicity Endocrine Disruption General toxicity



## Measuring Network Formation on Microelectrode Arrays





Microelectrode Array (MEA) Recording

- Planar microelectrodes are non-invasive
- Records electrical activity of any tissue type
- Repeated recordings from same sample

The electrical activity recorded by MEAs are the biological underpinnings of EEG recordings.

#### "Brain-on-a-Chip": Complex 2D model

- Rat cortical neural networks
- Contains neurons & glia cells
- Spontaneous activity
- Develops rapidly in vitro
- Follow network development over time
- Integrates activity of multiple processes



A snapshot in time of neural network activity in one well. Each box represents the electrical activity of neurons on 1 electrode in the array.

8

## **MEAs Measure Multiple Characteristics of Network Formation**



**EPA** 

In the Network Formation Assay (NFA), 19 endpoints describing network activity (17) and cytotoxicity (2) are measured over 12 days in vitro. These can increase or decrease following chemical exposure.

**General Activity**- overall rate of firing or bursting; measured on each electrode and averaged across the well.

**Bursting Structure-** the length and number of events in a burst; measured on each electrode and averaged across the well.



**Action Potential** "Spikes"/burst

**Connectivity**- Communication of information across electrodes (Correlation coefficients, Network Spikes, Mutual Information); averaged for the well.



## PFAS Compounds Tested for Effects on Network Formation

## **Test Set of Compounds**

- Original PFAS 150
  - 75 tested in concentration-response (0.03-30 μM)
- Re-procured PFAS
  - 131 Tested single-concentration (30 μM)
  - 42 tested in concentration-response (0.03-30 μM)
- 13 compounds tested as biological replicates

## Only a fraction of PFAS compounds disrupt network formation



**EPA** 

- ~25% of tested compounds were active
- No PFAS compound increased network formation parameters compared to control wells
- Three Groups: 1) "Pan Active" 2) subset of parameters 3) Inactive
- Positive and negative controls gave appropriate responses.
- Replicates gave generally consistent results
- Cytotoxicity was prominent in "Pan Active"

## Calculating a 'selectivity' metric

Selectivity: activity at concentrations lower than cytotoxicity.



## Selectivity of PFAS Compounds indicates that General activity and Network Connectivity are Altered more than Bursting



**SEPA** 

## Comparison of PFAS AC<sub>50</sub> to Other Compounds in the NFA



The potency of active PFAS compounds is near the median of potencies for all compounds tested in the NFA

**SEPA**

14



The NFA identified PFAS compounds that disrupt the formation of neural networks in vitro

- This identifies compounds with a potential *hazard* for DNT
- Can place the potency of these effects into context with other DNT compounds
- Exposures to these compounds have not been considered.

#### These data\* can be used to make inferences for a broader landscape of PFAS:

- Chemical Category and Read-across approaches for additional hazard identification/characterization.
- Bioactive Dose Level (BDL) Approach (*in vitro* to *in vivo* extrapolation to define administered dose equivalent (ADE) values)

\*Data are currently being analyzed across all of the different toxicities evaluated.

**€PA**

### Example #2: Using DNT NAMs to evaluate structure-activity relationships

#### **EPA's Office of Pesticide Programs (OPP)**

- Registers pesticides for use in the United States.
- Two new compounds (Compound Y, Z)
  - potentially neurotoxic.
  - A DNT Guideline study existed for "compound X" that was structurally similar to the novel compounds.
    - The DNT Study showed small but statistically significant changes in brain morphology
  - Literature data indicated that compound X caused acute neurotoxicity in vivo and altered network activity in vitro following acute exposure.

#### OPP needed to decide whether to request DNT Guideline studies on the new compounds

OPP asked EPA's Office of Research and Development to provide data to inform their decision with compounds Y and Z.

- Neurite Outgrowth and Network Formation assays were selected based on the of activity of compound X in Guideline Study and in vitro, respectively.
- Compounds X, Y and Z were tested in these assays, along with appropriate controls

## Compound X and analogs lack effects on Neurite Outgrowth



\*EX000371 = Compound X

Sepa

Conclusion: Compound X and analogs have no effects on neurite outgrowth

![](_page_17_Picture_0.jpeg)

## Compound X and analogs lack effects on Network Formation

![](_page_17_Figure_2.jpeg)

Conclusion: Compound X (EX000371) and analogs have no effects on Network Formation

![](_page_18_Picture_0.jpeg)

#### Acute Effects on Network Function

![](_page_18_Figure_2.jpeg)

S-PA

![](_page_18_Figure_3.jpeg)

Compound X (EX000371) had previously been shown to increase weighted mean firing rate in rat cortical neurons. These data demonstrate the biological activity of Compound X and its analogs. From Guideline study, NOAEL of Compound X = **14 mg/kg/day** 

Using HTTK and IVIVE

- $1 \text{ mg/kg/day} = \text{Css values of } 0.66 \text{ and } 2.21 \mu\text{M}$  in rats and humans, respectively
- 30 μM Compound X = AED of 45 mg/kg/day (rats) and 13.5 mg/kg/day (humans)

Summary: At concentrations equivalent to or above the NOAEL from in vivo studies, Compound X and analogs did not alter Neurite Outgrowth or Network Formation, but did have acute effects on Network Function

These data, along with other (e.g. exposure) data, were used to support a decision by OPP to waive the requirement for a DNT Guideline study for compounds Y and Z

![](_page_20_Picture_0.jpeg)

Organophosphate (OP) insecticides are currently regulated based on inhibition of acetylcholinesterase (AChE).

Primary Questions:

- 1. Does the DNT battery indicate that regulation based on AChE inhibition may not be health protective?
- 2. Can data from the DNT battery contribute to a Weight of Evidence (WOE) approach for OPs?

![](_page_21_Picture_0.jpeg)

## Example #3: Organophosphates and DNT

Study Design:

Test 27 Organophosphate insecticides in the EPA DNT assays 8 Parent/oxon pairs Concentration-response up to 100 μM Pipeline results through TCPL to generate AC<sub>50</sub> values Use HTTK to convert AC<sub>50</sub> values to AED<sub>50</sub> values Compare to BMD/BMDL10 values based on AChE inhibition

Assays:

Proliferation Apoptosis Neurite initiation Neurite initiation Neurite maturation Synaptogenesis Network formation (MEA) Behavior/Anatomy human neuroprogenitors (hNP1)

- human neuroprogenitors (hNP1)
- human neurons (hN2)
  - rat primary neural culture
  - rat primary neural culture
  - rat primary neural culture
  - rat primary neural culture

High-Content Imaging (HCI) assays

zebrafish (data analysis pending)

## OPs demonstrate differential responses in the HCI assays.

![](_page_22_Figure_1.jpeg)

**SEPA** 

- Cluster 1: negative or with effects in 1-3 endpoints.
- Cluster 2: effects on 5 or more assay endpoints
- Cluster 3: effects on all HCI assay activity types except for NOG initiation in hN2 cells and synaptogenesis in cortical cells
- Cluster 4: widespread effects across activity types

## Most OPs decreased MEA NFA activity

![](_page_23_Figure_1.jpeg)

÷ EP

- Top active cluster of OPs contains oxon and non-oxon structures.
- These OPs, like the assay performance controls and many other compounds, appear to generally decrease all activity types and most assay endpoints.
- Bottom cluster with minimal actives appears somewhat driven by cytotoxicity in the LDH assay.
- Negative- 0 assay endpoints altered
- Equivocal- 1-3 assay endpoints altered
- Positive- >3 assay endpoints altered

## HCI and MEA\_NFA assays show consistent results

DTXSID	Chemical	MEA NFA				НСІ			
		Neg	Equiv	Pos	1	2	3	4	
DTXSID8023846	Acephate	Х	Х		х				
DTXSID9032329	Bensulide			Х				Х	
DTXSID2032344	Chlorethoxyfos			Х			Х		
DTXSID4020458	Chlorpyrifos			X,X				Х	
DTXSID1038666	Chlorpyrifos oxon	х		Х		х			
DTXSID2020347	Coumaphos			Х				X	
DTXSID9020407	Diazinon		Х	Х		Х			
DTXSID5037523	Diazoxon		Х		Х				
DTXSID5020449	Dichlorvos		Х		х				
DTXSID9023914	Dicrotophos		Х		Х				
DTXSID7020479	Dimethoate			х		Х			
DTXSID4032611	Ethoprop			Х	х				
DTXSID0034930	Fosthiazate		Х		Х				
DTXSID9020790	Malaoxon	Х			Х				
DTXSID4020791	Malathion			X				Х	
DTXSID6024177	Methamidophos	Х	Х			Х			
DTXSID1024209	Naled			Х			X		
DTXSID4037580	Omethoate		Х		Х				

⇒ FPA

DTXSID		Chemical	Neg	Equiv	Pos	1	2	3	4
DTXSID403	32459	Phorate			Х		Х		
DTXSID502	24261	Phosmet			х		Х		
DTXSID002	24266	Pirimiphos-methyl			Х				x
DTXSID303	32464	Profenofos		Х		Х			
DTXSID103	32482	Tebupirimfos			х	Х			
DTXSID202	22254	Terbufos			Х			Х	
DTXSID102	24174	Tribufos			Х			Х	
DTXSID002	21389	Trichlorfon			х		Х		
DTXSID103	32648	Z- Tetrachlorvinphos			х				x

- Equiv or Pos in MEA NFA and negative in HCI: Acephate, diazoxon, dichlorvos, dicrotophos, fosthiazate, malaoxon, omethoate, profenofos
- Positive in MEA NFA and negative in HCI: Ethoprop
- *Positive in HCI and negative in MEA NFA:* OP chemical (methamidophos) was neg/equiv in the MEA NFA
- If activity is observed in the HCI assays, it is likely that the OP chemical will also be active in the MEA NFA.

## **\$EPA**

# For some OPs, DNT-NAM AC<sub>50</sub> < bioactivity estimate from the rest of ToxCast.

5th-%ile ToxCast AC50

٠

Min DNT-NAM AC50

Burst

DNT-NAM battery may provide a more potent estimate of bioactivity for substances with minimum DNT-NAM AC50 < 5<sup>th</sup> percentile of filtered ToxCast AC50 values:

- Chlorpyrifos and chlorpyrifos oxon
- Acephate
- Dichlorvos
- Terbufos
- Diazoxon
- Methamidophos

Suggests that the DNT-NAM battery, in covering some new biology not previously in ToxCast, may yield bioactivity threshold concentrations lower than what is already available for some neuroactive substances in ToxCast.

![](_page_25_Figure_10.jpeg)

![](_page_26_Picture_0.jpeg)

## AED50 to BMD/BMDL10 comparisons

![](_page_26_Figure_2.jpeg)

## **SEPA**

F

## Summary of the AED50 to BMD/BMDL comparison

	Chemicals with AED50 values >>> BMD/BMDL comparator	Chemicals with lowest AED50 within 1 log10 order of magnitude of BMD/BMDL comparator	Chemicals with lowest AED50 approaching BMD/BMDL comparator	Missing in vitro data for comparison
Rat/HuRat	Coumaphos, diazoxon, dicrotophos, ethoprop, fosthiazate, omethoate	acephate, bensulide, chlorpyrifos, chlorpyrifos oxon, diazinon, dimethoate, malathion, methamidophos, and phorate	<u>dimethoate</u> and <u>methamidophos</u> (lower quartile of huRat AED <sub>50</sub> values <u>dichlorvos</u> (huRat AED <sub>50</sub> ; only one positive rat assay endpoint) overlaps with the BMDL10 value, and it was not based on selective bioactivity in the DNT-NAM battery. <u>malathion (huRat AED<sub>50</sub> (selective) for also approach the BMD/BMDL10 values.</u>	Malaoxon (negative in all assays)
Human	bensulide, chlorpyrifos, chlorpyrifos oxon, coumaphos, diazinon, dimethoate, malathion, methamidophos, phosmet, pirimiphos- methyl, tribufos, and trichlorfon		<ul> <li><u>dichlorvos</u>, only two AED<sub>50</sub> values are available for comparison, and these values are centered around the BMD10/10 and BMDL10/10 values.</li> <li><u>terbufos</u>, only 3 human AED<sub>50</sub> values are available for comparison, and the lowest one of these values approaches the BMD10/10 value.</li> </ul>	Negative in all assays with human cells: Acephate, diazoxon, dicrotophos, ethoprop, fosthiazate, omethoate, phorate, profenofos, and tebupirimfos Malaoxon was negative

in all assays.

![](_page_28_Picture_0.jpeg)

- Overall, the BMDs for AChE inhibition are lower than those for DNT NAMS
  - This **decreases uncertainty** that the AChE values are health protective
- DNT NAM AED50 values approached the AChE BMD values for some compounds (dichlorvos, dimethoate, malathion)
- In 2020, a Scientific Advisory Panel reviewed these data and determined that NAMs can be used as part of a weight of evidence approach for decision-making regarding DNT.
- Future Direction- these OPs will be tested in the other DNT NAMs in the battery in the next year.

## **\$**EPA

## **Overall conclusion**

The development of a DNT-NAM battery for assessing potential DNT hazard:

- Provides an opportunity to overcome some of the challenges with the *in vivo* DNT guideline
- Evaluates critical processes underlying neurodevelopment
- Incorporates human relevant information

DNT NAMs are being utilized at the EPA for a variety of regulatory decision-making processes

## **\$EPA**

## Thank you! Questions?

#### **EPA ORD Colleagues:**

- Kathleen Wallace
- Theresa Freudenrich
- Bill Mundy (retired)
- Josh Harrill
- Jasmine Brown
- Katie Paul Friedman
- Melissa Martin
- Kelly Carstens (ORISE)
- Amy Carpenter (ORISE)
- Seline Choo (ORISE)
- Richard Judson
- Grace Patlewicz

#### **EPA Program Office Colleagues**

- Anna Lowit
- Liz Mendez
- Monique Perron
- Sarah Dobreniecki
- Mike Metzger

#### **EFSA Collaborators**

- Ellen Fritsche
- Marcel Leist